MOTS-c

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide made from instructions in mitochondrial DNA, the small separate genome inside the cell's energy-producing structures. That is unusual. Almost all of the body's signaling peptides are coded in the nucleus. The name stands for mitochondrial open reading frame of the 12S rRNA type-c.

It was described in 2015 by Changhan Lee, Pinchas Cohen and colleagues at the University of Southern California. Along with humanin, it helped establish the idea of mitochondrial-derived peptides, small signals that let mitochondria talk to the rest of the cell and the body.⁴

MOTS-c is not an approved drug. It is sold online as a research chemical and promoted for fat loss, insulin sensitivity, endurance and longevity, largely on the strength of mouse studies. It is often called an exercise mimetic. That label is a hypothesis drawn from animal work. No study has shown that MOTS-c given to people reproduces the broad benefits of regular physical activity.

How MOTS-c works

Think of MOTS-c as a stress messenger from your mitochondria. When cells are under metabolic strain, MOTS-c levels rise and it nudges the cell toward burning more glucose and fat for fuel. In mice, its main target appears to be skeletal muscle, where it improves how muscle handles glucose.⁴ Exercise raises it, and blood levels fall with age, which is where the longevity interest comes from.

Under stress, MOTS-c also moves into the cell nucleus and changes the activity of many genes involved in metabolism and stress resistance.²

In more detail, MOTS-c inhibits the folate cycle and the linked de novo purine synthesis pathway. This causes a buildup of AICAR, an intermediate that activates AMP-activated protein kinase (AMPK), the cell's main energy sensor. AMPK activation increases glucose uptake and fatty acid oxidation. Under metabolic stress, MOTS-c translocates to the nucleus in an AMPK-dependent way and interacts with stress-responsive transcription factors such as NRF2. Its mechanism overlaps with that of metformin, which also acts partly through AMPK.⁸

What the research shows on MOTS-c

Most of the evidence is from mice and cells. In mouse studies, MOTS-c injections prevented diet-induced obesity and insulin resistance, and improved physical performance in older animals.⁴ Reviews describe potential benefits across diabetes, cardiovascular disease, osteoporosis, postmenopausal obesity and Alzheimer's disease models.² A 2023 review noted that despite this, no effective method of using MOTS-c in the clinic has been developed.⁵

Interest has spread to lung disease. Reviews report lower circulating MOTS-c in acute respiratory distress and chronic conditions such as COPD and asthma, and protective effects of the peptide in animal models of lung injury and fibrosis.³¹ These are associations and animal findings, not treatment results in people.

Human data is limited to measuring natural MOTS-c levels. In one study of breast cancer patients randomized to metformin or not, circulating MOTS-c did not change significantly with treatment.⁸ The assays used to measure MOTS-c in blood vary, which makes these studies harder to compare. Small exercise studies in people have found that MOTS-c rises in muscle and blood during and after exercise, which supports the idea that it is part of the body's exercise response, but they do not test giving it as a drug. A modified analog developed by a biotech company reached early human testing but did not progress to approval.

Not all findings are favorable. One lab study found that MOTS-c and humanin increased the inflammatory secretions of senescent cells, which complicates the anti-aging story.⁶ A 2026 sports medicine review grouped MOTS-c with other unapproved peptides that look promising in animals but lack rigorous human safety data.⁷

Studied for: Metabolic health research, Insulin sensitivity, Exercise capacity research, Longevity.

MOTS-c reference data

MOTS-c dosage in published research

Open this in the dosage calculator ↗

How MOTS-c is used in practice

MOTS-c is not FDA approved, and it is not a recognized compounding ingredient, so legitimate US pharmacies cannot supply it for patient use. Some wellness clinics have offered it anyway. Most users buy freeze-dried vials from research-chemical sites, mix them with bacteriostatic water and inject under the skin a few times a week, usually for several weeks at a time.

Doses used by consumers are in the milligram range, much larger than for most research peptides, so vials are costly. No human dose-finding study supports them.

Quality control is the usual gray-market problem. Identity, purity, peptide content and sterility are not verified, and a vendor's certificate of analysis is not independent proof. Some sellers package MOTS-c into longevity stacks with other mitochondrial peptides such as SS-31 or humanin analogs. Combining several unstudied peptides makes it impossible to tell what is helping or causing harm.

MOTS-c risks and side effects

Without human trials, side effects are known only from user reports. These include injection-site redness and soreness, fatigue and headache. Whether larger risks exist is unknown.

Because MOTS-c lowers blood glucose in animals and acts through AMPK, combining it with metformin or other diabetes drugs could add to their effects, so blood sugar is worth watching. It should be avoided in pregnancy and by anyone with a known allergy to the product. Its effects on senescent cells and inflammation are not fully understood.⁶

Injecting unregulated products adds risks of infection, contamination and wrong dosing.

Reported side effects

Alternatives to MOTS-c

The most reliable way to raise your own MOTS-c, and get the metabolic benefits it is linked to, is exercise. Regular aerobic and resistance training improves insulin sensitivity, endurance and body composition at any age.

For people with insulin resistance or type 2 diabetes, metformin is inexpensive, well understood and also activates AMPK. GLP-1 based drugs such as semaglutide and tirzepatide are approved for weight loss and diabetes with large outcome trials behind them. SGLT2 inhibitors are another approved option for diabetes. Losing excess weight, improving diet quality and sleeping enough also improve the same metabolic markers that MOTS-c is studied for.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?